Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans-Reference-Cited by-同舟云学术

Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans

Published:2012-08-30 Issue:12 Volume:40 Page:2250-2255
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Bathala Mohinder S.,Masumoto Hiroshi,Oguma Toshihiro,He Ling,Lowrie Chris,Mendell Jeanne

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference16 articles.

1. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality;Cohen;Thromb Haemost,2007

2. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty

3. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles;Furugohri;J Thromb Haemost,2008

4. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

5. Masumoto H Yoshigae Y Watanabe K Takakusa H Okazaki O Izumi T (2010) In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. AAPS J 12 (Suppl 2):Abstract W4308.

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct oral anticoagulants in cirrhosis: Rationale and current evidence;JHEP Reports;2024-08

2. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08

3. Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?;The Pharmacogenomics Journal;2024-03-05

4. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers;Clinical Pharmacokinetics;2024-02-23

5. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants;Expert Opinion on Drug Metabolism & Toxicology;2023-11-24